Pharmaceutical

Kezar and Everest enter lupus nephritis therapy development deal

Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.

Sep 21, 2023 - 20:00
Kezar and Everest enter lupus nephritis therapy development deal
Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.
Read the original article

Tags:

Previous Article

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with ana...

Next Article

FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Newly diagnosed cancer patients need help navigating the system

Opinion: Newly diagnosed cancer patients need help navi...

May 31, 2023

More colonoscopy news and research

More colonoscopy news and research

Nov 29, 2023

J&J drops Addex’s epilepsy treatment after flunking in Phase II

J&J drops Addex’s epilepsy treatment after flunking in ...

Jul 24, 2024